Many diseases lack vaccines or have poor vaccines requiring multiple doses due to insufficient immune responses. VaxaBoost's proprietary adjuvant platforms will enable the development of novel vaccines (Respiratory Syncytial Virus) as well as the improvement of existing vaccines (Anthrax). VaxaBoost's lead products are currently in pre-clinipartnerships cal development. It seeks financing to ready its assets for licensing and/or with major pharmaceutical companies.
Missing: Vaxaboost's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vaxaboost's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Vaxaboost Frequently Asked Questions (FAQ)
Where is Vaxaboost's headquarters?
Vaxaboost's headquarters is located at Raleigh.
What is Vaxaboost's latest funding round?
Vaxaboost's latest funding round is Unattributed.
Who are the investors of Vaxaboost?
Investors of Vaxaboost include Duke Start-up Challenge.
Who are Vaxaboost's competitors?
Competitors of Vaxaboost include MolecularMD, Mersana Therapeutics, Arbovax, Rhenovia Pharma, Allozyne and 9 more.
Compare Vaxaboost to Competitors
Arbovax has a unique technology that modifies arthropod-borne viruses (arboviruses) making them unable to replicate in mammalian cells. Arbovax will leverage this technology through partnerships with pharmaceutical companies to facilitate the development of a portfolio of new and improved human vaccines against the worldwide threat of arthropod-borne diseases. Arbovax will focus on the research and development of a unique and proprietary technology that can be used to make vaccines to target unmet clinical needs in markets that have traditionally been neglected by major vaccine producers. Arbovax intends to engage in the preclinical and clinical development of vaccine products for the prophylactic treatment of arthropod-borne diseases that collectively infect over 100 million people annually and put over 2.5 billion people at risk of infection. The business strategy of the Company is to develop the technology to a point where it can be licensed to commercial partners for manufacture and distribution. Arbovax's patent-protected technology is based upon multiple deletions in the transmembrane portion of the virus allowing it to replicate in insect cells, but not in mammalian cells.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Armgo Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. The company's proprietary drugs, known as rycals, are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycals act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain.
NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).
NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.
Plymouth Marine Laboratory (PML) has been conducting research into marine organisms for more than 20 years funded by NERC. EcoAlert Ltd has been formed by PML's wholly owned technology transfer company, Plymouth Marine Applications Ltd (PMA), to commercialise a bioassay technique arising from this work. The Company has exclusive rights to ECOBOX, a portable bioassay kits for in-situ analysis of marine, estuarine and freshwater aquatic environments.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.